Key Highlights
- Second quarter 2026 net loss narrowed to USD 13.9 million, or USD 0.14 per share, from USD 31.2 million, which equalled USD 0.41 per share, a year earlier.
- Cash, restricted cash, cash equivalents and marketable securities totalled USD 155.2 million on June 30, 2026, and management expects that sum to fund operations into the second quarter of 2028.
- Revenue of USD 5.7 million was booked in the second quarter of 2026 with none in the prior-year period, while total operating expenses dropped to USD 21.2 million from USD 32.2 million.
- The company anticipates starting Phase 1 testing of PRT13722, a KAT6A degrader given orally for HR+ breast cancer, in the fourth quarter of 2026, once IND clearance comes through.
Narrower Loss and First Revenue Shape Expectations for Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) plans to release third quarter 2026 numbers on November 16, 2026, with the second quarter as the reference. That quarter's net loss shrank about 55.4% on a calculated basis, falling to USD 13.9 million from USD 31.2 million. The USD 5.7 million of revenue had no counterpart a year earlier, and deferred revenue was USD 25.2 million at June 30, 2026. Weighted average shares climbed to 98,388,593 from 75,993,941, a change that helped push the loss per share down to USD 0.14 from USD 0.41.
Lower Research Spend and Pipeline Progress at Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Research and development spending dropped to USD 16.1 million from USD 25.8 million, while general and administrative costs eased to USD 5.0 million from USD 6.4 million. The operating loss narrowed to USD 15.5 million from USD 32.2 million, and other income, net, rose to USD 1.5 million from USD 1.0 million. In February 2026 the company received IND clearance for PRT12396, a mutant-selective JAK2V617F inhibitor, and is now enrolling Phase 1 patients with polycythemia vera and myelofibrosis. Prelude Therapeutics Incorporated (NASDAQ:PRLD) says that program falls under an exclusive option deal with Incyte, which was made public in November 2025.
Balance Sheet Position and Incyte Option Exposure at Prelude Therapeutics Incorporated (NASDAQ:PRLD)
On June 30, 2026, cash and cash equivalents stood at USD 26.3 million and marketable securities at USD 125.4 million, while total Assets reached USD 189.4 million against liabilities of USD 55.6 million and shareholders' Equity of USD 133.7 million. An accumulated Deficit of USD 707.4 million sits behind those figures. No numeric financial guidance has been issued. Exposure includes early-stage trial risk, reliance on IND clearance for PRT13722, the unpredictable use of the Incyte option, collaboration income that might not continue, and the probability of raising more Capital beyond the second quarter of 2028.
Where Things Stand
Heading into its November 16, 2026 release, Prelude Therapeutics Incorporated (NASDAQ:PRLD) carries a slimmer cost structure and a funding horizon longer than a year ago. Quarterly operating costs dropped from USD 32.2 million to USD 21.2 million, and cash of USD 155.2 million is seen lasting into the second quarter of 2028. Shareholders will track the Phase 1 study of the JAK2V617F inhibitor, IND clearance and the fourth quarter start planned for the KAT6A degrader PRT13722, developments on the Incyte option, and whether revenue can keep pace after USD 5.7 million in the second quarter.
_11_16_2026_11_23_12_237620.jpg)


_11_16_2026_07_52_44_870464.jpg)


Please wait processing your request...